40915-27-3

Basic information

• Product Name: (3,4,5-TRIMETHOXYBENZOYL)AMINO]ACETIC ACID
• Synonyms: N-(3,4,5-TRIMETHOXYBENZOYL)GLYCINE;2-[(3,4,5-trimethoxybenzoyl)amino]acetic acid;2-[(3,4,5-trimethoxyphenyl)carbonylamino]ethanoic acid;2-[[oxo-(3,4,5-trimethoxyphenyl)methyl]amino]acetic acid
• CAS NO: 40915-27-3
• Molecular Formula: C₁₂H₁₅NO₆
• Molecular Weight: 269.26
• Mol File: 40915-27-3.mol

Chemical Properties

• Boiling Point: 417.4°Cat760mmHg
• Flash Point: 206.3°C
• Appearance: /
• Density: 1.264g/cm³
• Vapor Pressure: 1.03E-07mmHg at 25°C
• CAS DataBase Reference: (3,4,5-TRIMETHOXYBENZOYL)AMINO]ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (3,4,5-TRIMETHOXYBENZOYL)AMINO]ACETIC ACID(40915-27-3)
• EPA Substance Registry System: (3,4,5-TRIMETHOXYBENZOYL)AMINO]ACETIC ACID(40915-27-3)

Safety Data

• Hazardous Substances Data: 40915-27-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
(3,4,5-Trimethoxybenzoyl)amino]acetic acid is utilized as a key intermediate in the synthesis of pharmaceutical compounds, contributing to the development of new drugs. Its unique structure allows it to interact with biological targets, potentially leading to the discovery of novel therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (3,4,5-Trimethoxybenzoyl)amino]acetic acid is employed as a building block for designing and optimizing drug candidates. Its chemical properties enable it to modulate biological pathways and mechanisms, offering a promising avenue for the treatment of various diseases and conditions.
Used in Drug Synthesis:
(3,4,5-Trimethoxybenzoyl)amino]acetic acid is used as a starting material in the synthesis of pharmaceutical compounds, providing a foundation for the creation of new and effective drugs. Its presence in these compounds can enhance their pharmacological properties, such as potency, selectivity, and bioavailability.
Used in Industrial Applications:
Beyond its pharmaceutical applications, (3,4,5-Trimethoxybenzoyl)amino]acetic acid may also find use in other industries due to its unique chemical properties. Its potential applications in areas such as material science, chemical engineering, and environmental science are currently being explored, highlighting its versatility and broad utility.

InChI:InChI=1/C12H15NO6/c1-17-8-4-7(12(16)13-6-10(14)15)5-9(18-2)11(8)19-3/h4-5H,6H2,1-3H3,(H,13,16)(H,14,15)/p-1

Upstream product

• 92502-39-1 ethyl ((3,4,5-trimethoxybenzoyl)amino)acetate 
• 4521-61-3 3,4,5-Trimethoxybenzoyl chloride 
• 56-40-6 glycine 
• 118-41-2 Eudesmic acid 
• 57710-78-8 (1H?1,2,3?benzotriazol?1?yl)(3,4,5?trimethoxyphenyl)methanone 
• 3086-62-2 3,4,5-trimethoxybenzamide 
• 56593-75-0 N-(3,4,5-trimethoxy-benzoyl)-glycine nitrile 

Downstream Products

• 6754-97-8 N-(3,4,5-trimethoxy-benzoyl)-glycine dimethylamide 
• 106360-33-2 1-[N-(3,4,5-trimethoxy-benzoyl)-glycyl]-pyrrolidine 
• 100254-94-2 N-(3,4,5-trimethoxy-benzoyl)-glycine amide 

Relevant articles and documents

Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect

A new series of quinoline derivatives of combretastatin A-4 have been designed, synthesised and demonstrated as tubulin polymerisation inhibitors. These novel compounds showed significant antiproliferative activities, among them, 12c exhibited the most potent inhibitory activity against different cancer cell lines (MCF-7, HL-60, HCT-116 and HeLa) with IC50 ranging from 0.010 to 0.042 μM, and with selectivity profile against MCF-10A non-cancer cells. Further mechanistic studies suggest that 12c can inhibit tubulin polymerisation and cell migration, leading to G2/M phase arrest. Besides, 12c induces apoptosis via a mitochondrial-dependant apoptosis pathway and caused reactive oxygen stress generation in MCF-7 cells. These results provide guidance for further rational development of potent tubulin polymerisation inhibitors for the treatment of cancer.Highlights A novel series of quinoline derivatives of combretastatin A-4 have been designed and synthesised. Compound 12c showed significant antiproliferative activities against different cancer cell lines. Compound 12c effectively inhibited tubulin polymerisation and competed with [3H] colchicine in binding to tubulin. Compound 12c arrested the cell cycle at G2/M phase, effectively inducing apoptosis and inhibition of cell migration.

Potent combretastatin A-4 analogs containing 1,2,4-triazole: Synthesis, antiproliferative, anti-tubulin activity, and docking study

A series of cis restricted 1,2,4-triazole analogs of combretastatin A-4 (CA-4) were designed and synthesized. The antiproliferative activity of these compounds was measured on hepatocellular carcinoma HepG2, leukemia HL-60, and breast cancer MCF-7 cell li

Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation

Two structurally novel series of histone deacetylase inhibitors (HDACIs) involving two potential surface recognition moieties; 3′,4′-dihydro-2′H-spiro[imidazolidine-4,1′-naphthalene]-2,5-dione (in series I) and 1-(3-methoxyphenyl)-5-(3,4,5-trimethoxypheny

Design, synthesis, anticonvulsant activity, and pharmacophore study of new 1,5-diaryl-1H-1,2,4-triazole-3-carboxamide derivatives

1,5-Diaryl-1H-1,2,4-triazole-3-carboxamide derivatives were designed, synthesized, and evaluated for its anticonvulsant activity using maximal electroshock (MES) and chemoshock (scPTZ and Strychnine) animal screen methods. Neurotoxicity was also assessed. In MES model, compound 4f showed 100% of phenytoin activity after both 0.5 and 4 h. In scPTZ model, compound 4e showed 100% of sodium valproate activity. In Strychnine model, compound 4e showed 120% more delay of onset of convulsion and 124% more delay of time of death relative to sodium valproate. Most of the target compounds showed mild neurotoxicity especially compound 4f which showed excellent activity against electroshock. Pharmacophoric study reveals that the synthesized compounds showed good fitting on the pharmacophoric query with good RMSDX results.

Synthetic method for capobenic acid drug intermediate-epsilon-(3,4,5-trimethoxybenzoylamino)-acetic acid

The invention discloses a synthetic method for a capobenic acid drug intermediate-epsilon-(3,4,5-trimethoxybenzoylamino)-acetic acid. The method comprises the following steps: (i) adding 0.22-0.24mol of epsilon-amino acetic acid (3) and 40-50ml of a sodium chloride solution into a reaction container, controlling the stirring speed to be 110-160rpm, adding 100-130ml of a sodium sulfite solution, reducing the temperature of the solution to 6-9 DEG C, dropwise adding 0.1-6mol of 3,4,5-trimethoxybenzamide (2), after the addition of the 3,4,5-trimethoxybenzamide (2) is finished, reacting for 4-5 hours, performing molecular sieve decolorization, adding an oxalic acid solution to adjust the pH value of the solution to be 4-5, separating out solid, filtering, washing with a salt solution, performing dewatering with a dewatering agent, and performing re-crystallization in a nitromethane solution to obtain white powdery solid- epsilon-(3,4,5-trimethoxybenzoylamino)-acetic acid, wherein the mass percentage of the sodium sulfite solution in the step (i) is 55-60% and the mass percentage of the oxalic acid solution in the step (i) is 25-30%.

1-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3- carboxamides: Synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity

A series of novel 1-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4- triazole-3-carboxamides were synthesized and confirmed with different spectroscopic techniques. The prepared compounds exhibited remarkable anti-inflammatory activity that represen

Synthesis, cytotoxicity, docking study, and tubulin polymerization inhibitory activity of novel 1-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- 1h-1,2,4-triazole-3-carboxanilides

A series of novel 1-(3,4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2, 4-triazole-3-carboxylic acid derivatives (4a-n) were synthesized and evaluated for their in vitro cytotoxic activity against the growth of four different human cell lines (hepatoca